pharmazz

  • Clinical phase II results indicate that PMZ-2010 (centhaquin) is a novel highly effective resuscitative agent for hypovolemic shock

    May 17, 2018, - NAPERVILLE, Ill., May 17, 2018 /PRNewswire/ - Pharmazz, Inc. is pleased to announce interim analysis of a prospective, multi-centric, randomized, double-blind, parallel, saline controlled phase II study of PMZ-2010 (centhaquin) ...
    Read More
  • Notice of allowance issued for two Canadian patent applications and US Congressman Bill Foster visits Midwestern University

    March 30, 2018, - NAPERVILLE, Ill., March 30, 2018 /PRNewswire/ - Pharmazz, Inc. is pleased to announce that Notice of Allowance has been issued for Canadian Patent Application No. 2696398 titled "Methods for treatment of stroke or cerebrovascular accidents using an ET-B receptor agonist." PMZ-1620, a selective endothelin-B receptor agonist, is in clinical phase II trials in patients suffering from cerebral ischemia (stroke) and mild to moderate Alzheimer's disease...
    Read More
  • Issuance of patent and initiation of a study to evaluate PMZ-1620 in dogs with degenerative myelopathy, a disease similar to human amyotrophic lateral sclerosis (ALS)

    Jan. 11, 2018, - NAPERVILLE, Ill., Jan. 11, 2018 /PRNewswire/ - Pharmazz, Inc. is pleased to announce that Indian Patent No. 290038 on a pharmaceutical composition comprising IRL-1620 (PMZ-1620) was granted on November 28, 2017. PMZ-1620, a selective endothelin-B receptor agonist, is presently undergoing clinical studies in patients suffering from mild to moderate Alzheimer's disease. In addition, a phase II study, using PMZ-1620, is being conducted in patients with cerebral ischemic stroke...
    Read More
  • Pharmazz, Inc. has received exclusive license to U.S. patent for treatment of opioid tolerance and pain management

    Oct. 18, 2017, - NAPERVILLE, Ill., Oct. 18, 2017 /PRNewswire/ - Pharmazz, Inc. has received exclusive license to U.S. patent for treatment of opioid tolerance and pain management. Inadequate pain control is a major public health concern in the USA. Dr. Anil Gulati and his colleagues have been working on this technology since 2002, and have conducted extensive studies and demonstrated that endothelin-A receptor antagonists such as PMZ-2123 potentiate analgesic effects of morphine and oxycodone and eliminates tolerance to these drugs...
    Read More
  • Pharmazz, Inc. initiates human phase II studies of PMZ-2010 for the treatment of hemorrhagic shock and presents data at the Society of Critical Care Medicine Annual Meeting

    Feb 3, 2017 - NAPERVILLE, Ill., Feb. 3, 2017 /PRNewswire/ -- Pharmazz, Inc. is a clinical-stage company developing innovative therapeutics in the area of critical care medicine. The company has initiated a human phase II study in India to determine the efficacy of PMZ-2010 (centhaquin) in patients of hypovolemic shock....
    Read More
  • Pharmazz, Inc. advances its product pipeline for the treatment of stroke, strengthens patent portfolio and presents hemorrhagic shock data at the American Heart Association

    Nov 30, 2016 - NAPERVILLE, Ill., Nov. 30, 2016 /PRNewswire/ - Pharmazz, Inc. is a clinical-stage company developing innovative therapeutics in the area of critical care medicine. Results of the human safety and pharmacokinetics of PMZ-2010 were presented at the American Heart Association Scientific Sessions 2016...
    Read More
  • Pharmazz, Inc. strengthens its patent portfolio with Notice of Issuance for PMZ-2123 (BQ123) in the treatment of diabetic ketoacidosis

    Apr 22, 2016 - NAPERVILLE, Ill., April 22, 2016 /PRNewswire/ - Pharmazz, Inc. ... This press releasecontains "forward-looking statements" within the ...
    Read More